drugset / Trial / NCT00001035
The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections
Phase 1
Completed
10 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Schering-Plough · collab
Treatment
Summary
To investigate the toxicity of interferon alfa-2b ( IFN alfa-2b ) in combination with nucleoside analog therapy in HIV-positive patients with chronic hepatitis C. To determine the efficacy of treatment with IFN alfa-2b for chronic hepatitis C in patients with advanced HIV infections treated with nucleoside analog therapy. IFN alfa-2b has HIV inhibitory properties and has also been approved for treatment of chronic hepatitis C. Studies have shown that IFN alfa-2b is effective in asymptomatic HIV-positive patients with chronic hepatitis C, but the drug's benefit against hepatitis C in patients with advanced HIV infection has not been determined.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 1996-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | interferon alfa-2b | Protein / enzyme biologic | — | Subcutaneous |
| Background | Didanosine | Small molecule | — | — |
| Background | Zalcitabine | Small molecule | — | — |
| Background | Zidovudine | Small molecule | — | — |